Error in Figure/Table
In the original article, there was a mistake in Table 1 as published. For ‘Days from symptom onset to treatment,’ the IFN+ARB and ARB values were inadvertently switched. IFN+ARB should be 8.0 [5.0,11.0] and ARB should be 17.0 [10.0, 22.0]. The corrected Table 1 appears below.
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Table 1
| IFN n = 7 | IFN+ARB n = 46 | ARBn = 24 | p-value | |
|---|---|---|---|---|
| Age, yrs | 41.3 (27–68) | 40.4 (25–80) | 64.5 (37–73) | <0.001 |
| Male (%) Female (%) |
0 (0.0%) 7 (100%) |
20 (43.5%) 26 (56.5%) |
11 (45.8%) 13 (54.2%) |
0.076 |
| Comorbidities (%)a | 14.3% | 15.2% | 54.2% | 0.002 |
| Initial symptoms | ||||
| Fever (%) | 57.1% | 58.7% | 70.8% | 0.632 |
| Cough (%) | 42.9% | 50.0% | 54.2% | 0.888 |
| Fatigue (%) | 14.3% | 23.9% | 37.5% | 0.422 |
| Myalgia (%) | 14.3% | 13.0% | 29.2% | 0.228 |
| Headache (%) | 14.3% | 6.52% | 4.17% | 0.590 |
| Pharyngalgia (%) | 0.00% | 13.0% | 8.33% | 0.742 |
| Chest pain (%) | 14.3% | 6.52% | 20.8% | 0.134 |
| Expectoration (%) | 14.3% | 8.70% | 20.8% | 0.281 |
| Nausea (%) | 0.00% | 0.00% | 4.17% | 0.403 |
| Diarrhea (%) | 14.3% | 4.35% | 20.8% | 0.081 |
| Days from symptom onset to hospital admissionb | 8.0 [5.5, 15.5] |
6.5 [3.0, 10.0] |
10.0 [4.5, 19.5] |
0.087 |
| Days from symptom onset to 1st treatmentb | 8.0 [6.5, 16.00] |
8.0 [5.25, 11.0] |
17.0 [10.0, 22.0] |
<0.001 |
Demographics and clinical characteristics of patient cohort.
Hypertension, diabetes, COPD, chronic bronchitis, heart disease, cancer.
Median and interquartile range [Q1, Q3] are reported.
Summary
Keywords
interferon, COVID-19, viral shedding, IL-6, inflammation, ARDS
Citation
Zhou Q, Chen V, Shannon CP, Wei X-S, Xiang X, Wang X, Wang Z-H, Tebbutt SJ, Kollmann TR and Fish EN (2020) Corrigendum: Interferon-α2b Treatment for COVID-19. Front. Immunol. 11:615275. doi: 10.3389/fimmu.2020.615275
Received
08 October 2020
Accepted
09 October 2020
Published
27 October 2020
Approved by
Frontiers Editorial Office, Frontiers Media SA, Switzerland
Volume
11 - 2020
Updates
Copyright
© 2020 Zhou, Chen, Shannon, Wei, Xiang, Wang, Wang, Tebbutt, Kollmann and Fish.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Eleanor N. Fish, en.fish@utoronto.ca
This article was submitted to Viral Immunology, a section of the journal Frontiers in Immunology
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.